Monash Medical Centre

Running trials

• Recruiting

  Evaluation of XYA02 in Patients With Advanced Solid Tumors

  NCT07670312· Phase 1/2· Source

• Recruiting

  A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

  NCT07678593· Phase 1/2· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Source

• Recruiting

  A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

  NCT07469891· Phase 1· Source

• Recruiting

  Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

  NCT07493512· Phase 1· Source

• Recruiting

  Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

  NCT07531095· Phase 1· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  NCT07355218· Phase 3· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Source

• Active, not recruiting

  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

  NCT07225686· Phase 3· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

  NCT07278336· Phase 1· Source

• Active, not recruiting

  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

  NCT07226765· Phase 3· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  NCT07059845· Phase 2· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

  NCT07149857· Phase 2· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Source

• Recruiting

  A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

  NCT07147348· Phase 1/2· Source

• Recruiting

  AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

  NCT06959524· Source

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Source

• Recruiting

  A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  NCT07060807· Phase 3· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

  NCT06944522· Phase 3· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

  NCT06682988· Phase 2· Source

• Recruiting

  Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

  NCT06812715· Phase 2· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Active, not recruiting

  A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

  NCT06745323· Phase 2· Source

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Source

• Active, not recruiting

  A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

  NCT06456463· Phase 2· Source

• Recruiting

  Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

  NCT06750185· Phase 1/2· Source

• Recruiting

  International Care Bundle Evaluation in Cerebral Hemorrhage Research

  NCT06429332· Phase 4· Source

• Recruiting

  RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

  NCT06798896· Phase 2· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Source

• Recruiting

  A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

  NCT06768489· Phase 1· Source

• Recruiting

  CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  NCT06690775· Phase 2· Source

• Recruiting

  Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

  NCT07612280· Phase 1/2· Source

• Recruiting

  Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

  NCT06441747· Phase 2· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

  NCT06461897· Phase 3· Source

• Active, not recruiting

  A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT06508658· Phase 3· Source

• Active, not recruiting

  Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  NCT06332534· Phase 3· Source

• Not yet recruiting

  Australasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke

  NCT06495671· Source

• Active, not recruiting

  A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

  NCT06365853· Phase 2· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

  NCT06100744· Phase 3· Source

• Active, not recruiting

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· Phase 3· Source

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Source

• Recruiting

  Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke

  NCT05892510· Phase 2/3· Source

• Active, not recruiting

  Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06158841· Phase 3· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ovarian cancer7 recruiting
• Prostate cancer6 recruiting
• Lung cancer5 recruiting
• Stroke5 recruiting
• Liver and biliary tract cancer4 recruiting
• Multiple myeloma4 recruiting
• Colorectal cancer3 recruiting
• Crohn's disease3 recruiting
• Endometrial cancer3 recruiting
• Gastric and esophageal cancer3 recruiting
• Head and neck cancer3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Pancreatic cancer3 recruiting
• Childhood cancers2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Coronary artery disease2 recruiting
• Melanoma2 recruiting
• Psoriasis2 recruiting
• Triple-negative breast cancer2 recruiting
• Ulcerative colitis2 recruiting
• Acute myeloid leukemia1 recruiting
• Amyloidosis1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Cystic fibrosis1 recruiting
• Epilepsy1 recruiting
• Heart failure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• IgA nephropathy1 recruiting
• Lupus (SLE)1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Parkinson disease1 recruiting
• Psoriatic arthritis1 recruiting
• Sickle cell disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

  NCT06226805· Phase 2· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Source

• Terminated

  Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

  NCT06068868· Phase 1· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Source

• Completed

  A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)

  NCT05558696· Phase 2· Source

• Completed

  A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

  NCT05975073· Phase 1/2· Source

• Terminated

  A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

  NCT05317078· Phase 1· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Completed

  Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

  NCT05669599· Phase 2· Source

• Completed

  A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

  NCT05174221· Phase 1· Source

• Completed

  The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

  NCT05162586· Phase 2· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Source

• Completed

  A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

  NCT05002127· Phase 2/3· Source

• Completed

  Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

  NCT05041257· Phase 2· Source

• Completed

  A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

  NCT04779307· Phase 3· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Source

• Completed

  Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

  NCT04745026· Phase 2· Source

• Terminated

  Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

  NCT04807972· Phase 1· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Source

• Completed

  A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

  NCT04763408· Source

• Completed

  Alleviate-HF-2 Study

  NCT04838353· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

  NCT04744831· Phase 2· Source

• Completed

  A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

  NCT04657224· Phase 1· Source

• Completed

  Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

  NCT04472429· Phase 3· Source

• Completed

  A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

  NCT04451772· Phase 2· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Phase 2/3· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Source

• Completed

  A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

  NCT04083235· Phase 3· Source

• Completed

  A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

  NCT04138277· Phase 3· Source

• Completed

  A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

  NCT04169373· Phase 3· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Source

• Completed

  ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

  NCT03685448· Phase 2· Source

• Completed

  A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT03900598· Phase 1· Source

• Terminated

  Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

  NCT03646123· Phase 2· Source

• Completed

  Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

  NCT03710876· Phase 3· Source

• Completed

  Vocal Cord Responses During Hyperventilation in Normal Individuals and in Mild and Severe Asthmatics.

  NCT05565430· Source

• Completed

  Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491· Phase 3· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· Source

• Completed

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· Phase 3· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Source

• Completed

  Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

  NCT02910583· Phase 2· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Source

• Completed

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· Phase 3· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Source

Trial sites

• 0360092 - Monash Medical Centre1 trial
• Monash Health (Monash Medical Centre)19 trials
• Monash Health, Monash Medical Centre (Clayton)1 trial
• Monash Health - Monash Medical Centre - Clayton /ID# 2012631 trial
• Monash Health - Monash Medical Centre - Clayton /ID# 2444031 trial
• Monash Health - Monash Medical Centre - Clayton /ID# 2547261 trial
• Monash Health - Monash Medical Centre - Clayton /ID# 2602551 trial
• Monash Health - Monash Medical Centre - Clayton /ID# 2621581 trial
• Monash Health - Monash Medical Centre - Clayton /ID# 2628781 trial
• Monash Health - Monash Medical Centre - Clayton /ID# 2671491 trial
• Monash Health - Monash Medical Centre - Clayton /ID# 2693041 trial
• Monash Health - Monash Medical Centre - Clayton /ID# 2722341 trial
• Monash Health - Monash Medical Centre - Clayton /ID# 2769841 trial
• Monash Health - Monash Medical Centre - Clayton /ID# 2814681 trial
• Monash Health - Monash Medical Centre /ID# 1502181 trial
• Monash Health - Monash Medical Centre /ID# 2245991 trial
• Monash Health - Monash Medical Centre /ID# 2256801 trial
• Monash Health - Monash Medical Centre /ID# 2463661 trial
• Monash Health - Monash Medical Centre /ID# 2538411 trial
• Monash Health - Monash Medical Centre /ID# 2556781 trial
• Monash Health - Monash Medical Centre /ID# 2585381 trial
• Monash Health - Monash Medical Centre /ID# 2627831 trial
• Monash Health - Monash Medical Centre /ID# 2693601 trial
• Monash Health - Monash Medical Centre /ID# 2697351 trial
• Monash Health Translational Precinct, Monash Medical Centre1 trial
• Monash Heath - Monash University - Monash Medical Centre1 trial
• Monash Medical Center Clayton1 trial
• Monash Medical Centre91 trials
• Monash Medical Centre Clayton12 trials
• Monash Medical Centre - Haematology Department1 trial
• Monash Medical Centre /ID# 1142-05561 trial
• Monash Medical Centre /ID# 2080331 trial
• Monash Medical Centre /ID# 2080341 trial
• Monash Medical Centre /ID# 2155091 trial
• Monash Medical Centre /ID# 2218141 trial
• Monash Medical Centre /ID# 2313791 trial
• Monash Medical Centre (Site 0006)1 trial
• Monash Medical Centre (Site 0216)1 trial
• Monash Medical Centre (Site 2301)1 trial
• Monash Medical Centre1 trial
• Monash Medical Centre11 trials

Conditions

Diseases this institution publishes on or runs trials for.

• ANCA-associated vasculitis6 works · 0 trials